exendin-4 tirzepatide The incretin co-agonist requires GIPR for hormone secretion from human islets Tirzepatide: A Promising Drug for

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts

Women should report new menstrual irregularities, though such changes may reflect positive metabolic improvements rather than adverse effects

"Getting him on the medication meant we got ahead of those things, which is amazing because we have a family history of diabetes," says Ambiyo

Read more: Do insurance plans cover Zepbound

Your actual starting dose may differ

We understand that every step on your health journey requires careful consideration and expert guidance